Literature DB >> 31993956

Validation of multiparametric rubidium-82 PET myocardial blood flow quantification for cardiac allograft vasculopathy surveillance.

Sharon Chih1, Aun Yeong Chong2, Jordan Bernick3, George A Wells3, Robert A deKemp3, Ross A Davies4, Ellamae Stadnick4, Derek Y So2, Christopher Overgaard5, Lisa M Mielniczuk4, Rob S B Beanlands6.   

Abstract

BACKGROUND: We previously demonstrated high diagnostic accuracy of Rubidium-82 positron emission tomography (PET) myocardial blood flow (MBF) quantification for CAV. The purpose of this study was to validate multiparametric PET detection of CAV by combined rate-pressure-product-corrected myocardial flow reserve (cMFR), stress MBF, and coronary vascular resistance (CVR) assessment. METHODS AND
RESULTS: Diagnostic CAV cut-offs of cMFR < 2.9, stress MBF < 2.3, CVR > 55 determined in a previous study (derivation) were assessed in heart transplant recipients referred for coronary angiography and intravascular ultrasound (IVUS) (validation). CAV was defined as International Society of Heart and Lung Transplantation CAV1-3 on angiography; and maximal intimal thickness ≥ 0.5 mm on IVUS. Eighty patients (derivation n = 40, validation n = 40) were included: 80% male, mean age 54±14 years, 4.5±5.6 years post transplant. The prevalence of CAV was 44% on angiography and 78% on IVUS. Combined PET cMFR < 2.9, stress MBF < 2.3, CVR > 55 CAV assessment yielded high 88% (specificity 75%) and 83% (specificity 40%) sensitivity for ≥ 1 abnormal parameter and high 88% (sensitivity 59%) and 90% (sensitivity 43%) specificity for 3 abnormal parameters, in the derivation and validation cohorts, respectively.
CONCLUSION: We validate the diagnostic accuracy of multiparametric PET flow quantification by cMFR, stress MBF, and CVR for CAV.
© 2020. American Society of Nuclear Cardiology.

Entities:  

Keywords:  Cardiac allograft vasculopathy; Heart transplantation; Myocardial blood flow; PET

Mesh:

Substances:

Year:  2020        PMID: 31993956     DOI: 10.1007/s12350-020-02038-y

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  4 in total

1.  Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database.

Authors:  M R Costanzo; D C Naftel; M R Pritzker; J K Heilman; J P Boehmer; S C Brozena; G W Dec; H O Ventura; J K Kirklin; R C Bourge; L W Miller
Journal:  J Heart Lung Transplant       Date:  1998-08       Impact factor: 10.247

2.  Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy.

Authors:  M R Mehra; H O Ventura; D D Stapleton; F W Smart; T C Collins; S R Ramee
Journal:  J Heart Lung Transplant       Date:  1995 Jul-Aug       Impact factor: 10.247

3.  Serial Assessment of Coronary Flow Reserve by Rubidium-82 Positron Emission Tomography Predicts Mortality in Heart Transplant Recipients.

Authors:  Attila Feher; Ajay Srivastava; Michael A Quail; Nabil E Boutagy; Pravien Khanna; Lynn Wilson; Edward J Miller; Yi-Hwa Liu; Forrester Lee; Albert J Sinusas
Journal:  JACC Cardiovasc Imaging       Date:  2018-10-17

4.  Reduced Myocardial Flow Reserve by Positron Emission Tomography Predicts Cardiovascular Events After Cardiac Transplantation.

Authors:  Matthew C Konerman; John J Lazarus; Richard L Weinberg; Ravi V Shah; Michael Ghannam; Scott L Hummel; James R Corbett; Edward P Ficaro; Keith D Aaronson; Monica M Colvin; Todd M Koelling; Venkatesh L Murthy
Journal:  Circ Heart Fail       Date:  2018-06       Impact factor: 8.790

  4 in total
  1 in total

1.  Assessment of late-term progression of cardiac allograft vasculopathy in patients with orthotopic heart transplantation using quantitative cardiac 82Rb PET.

Authors:  Uttam M Shrestha; Maria Sciammarella; Miguel Hernandez Pampaloni; Elias H Botvinick; Grant T Gullberg; Teresa DeMarco; Youngho Seo
Journal:  Int J Cardiovasc Imaging       Date:  2020-10-29       Impact factor: 2.357

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.